GLPwatch
Response at 3 months to insulin dose decisions made at exenatide initiation in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit.
Diabetes Res Clin Pract · 2011
Last updated 2026-05-28In a nationwide study of 1,276 people with type 2 diabetes starting the GLP-1 drug exenatide, blood sugar control worsened in many when insulin was stopped completely. The findings suggest that insulin should not be stopped abruptly when starting exenatide, but instead reduced gradually only if blood sugar improves significantly after 3 months.
AI summary of the abstract below.
| Journal | Diabetes Res Clin Pract, 2011 |
|---|---|
| Citations | 15 |
| Relative citation ratio | 0.47 |
| NIH percentile | 28 |
| Molecules | exenatide |
| Conditions studied | Type 2 Diabetes |
Abstract
It is uncertain what should be done with insulin dose if starting exenatide. In the ABCD nationwide exenatide audit, many patients with type 2 diabetes had worsened glycaemia when insulin was stopped. If starting exenatide, insulin should not be stopped but weaned off only if there is significant glycaemic response.
Verbatim abstract via PubMed 21636161 ↗
Related research
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
- Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
- Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
- Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.
- Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction.
- Exenatide and the treatment of patients with Parkinson's disease.
- Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.
- Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.